“Orange Book” Listings Are Not Immune From Antitrust Scrutiny, FTC Says

"Orange Book" patent listings should not be afforded the same antitrust exemption given to "petitioning," the Federal Trade Commission maintains in an amicus curiae brief filed as part of a state attorneys general action against Bristol-Myers Squibb